In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Dr Boyd highlights details of the phase 3 DREAMM-7 trial, examining the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone for relapsed/refractory MM.
Study findings presented at ASH 2020 propose a recommended dose of CAEL-101 for use in combination with CyBorD in phase 3 clinical trials of patients with AL amyloidosis.
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Stay in the know.
OncNet Newsletter